MAPT and Alzheimer disease: Researchers are exploring quinazoline-based compounds for their potential to inhibit key enzymes and pathways involved in the pathogenesis of AD, such as acetylcholinesterase and beta-secretase, which play critical roles in the formation of amyloid plaques and tau tangles.